Actorius NGS Testing: Transforming Cancer Diagnostics in India.

Actorius Unveils New NGS Testing and OncoDiscover CTC Platform at CAMO 2026. Actorius Innovations and Research showcased its comprehensive liquid biopsy portfolio today at the CAMO 2026 – Cancer in Motion International Scientific Symposium, hosted at ACTREC, Tata Memorial Centre, Navi Mumbai. During the symposium, the firm introduced its next-generation sequencing (NGS) genomic tests aimed at supporting cancer treatment strategies, while emphasizing the synergistic value of its CDSCO-approved OncoDiscover circulating tumor cell biomarker technology.

These new NGS tests allow oncologists to refine treatment choices and track minimal residual disease over time by analyzing ctDNA, gDNA, and RNA. By integrating this with OncoDiscover—which identifies and counts rare circulating tumor cells via proprietary immunomagnetic enrichment and fluorescence microscopy—physicians receive a multi-analyte perspective on both the cellular and molecular indicators of the disease. Created under the scientific guidance of Dr. Jayant Khandare, OncoDiscover stands as India’s first and only CDSCO-cleared clinical assay for CTC detection from a simple blood sample, with utility across more than fifteen solid tumor types.

Global liquid biopsy pioneers Prof. Klaus Pantel and Prof. Catherine Alix-Panabières, who together coined the term "Liquid Biopsy" in 2010, lauded the integrated strategy during the symposium. Prof. Pantel observed that Actorius has effectively converted solid CTC science into a regulated platform, which, when paired with genomic testing, significantly broadens the availability of liquid biopsy for patients in India. Prof. Alix-Panabières praised the scientific rigor of merging OncoDiscover with NGS monitoring, describing it as a major advancement that incorporates high-quality circulating biomarker data into everyday clinical practice.

Dr. Jayant Khandare explained that circulating tumor cells and residual genomic signals can remain present and fuel future metastasis, even when imaging results appear clear. He noted that the combination of OncoDiscover and the new NGS tests offers quantitative cellular and molecular data from simple blood draws, assisting clinicians in tracking disease progression, directing targeted treatment, lowering reliance on imports, and increasing access to advanced monitoring. The product introduction and scientific dialogue at CAMO 2026 highlighted the importance of this dual-analyte method for dynamic treatment monitoring.